Some Evolus, Inc. (NASDAQ:EOLS) shareholders may be a little concerned to see that the President, David Moatazedi, recently sold a substantial US$822k worth of stock at a price of US$9.95 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 84% of their entire holding.

Check out our latest analysis for Evolus

The Last 12 Months Of Insider Transactions At Evolus

Over the last year, we can see that the biggest insider purchase was by Chairman of the Board Vikram Malik for US$1.3m worth of shares, at about US$7.41 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$9.78. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 2.2% of Evolus shares, worth about US$12m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Evolus Tell Us?

An insider sold Evolus shares recently, but they didn't buy any. In contrast, they appear keener if you look at the last twelve months. It's good to see insiders are shareholders. So we're not overly bothered by recent selling. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that Evolus is showing 3 warning signs in our investment analysis, and 1 of those doesn't sit too well with us...

But note: Evolus may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.